Cargando…

Clinical Significance and Systematic Expression Analysis of the Thyroid Receptor Interacting Protein 13 (TRIP13) as Human Gliomas Biomarker

SIMPLE SUMMARY: High expression of TRIP13 is associated with IDH-wild type gliomas. Patients with elevated TRIP13 levels are indicative of the poor survival outcome. The study aimed to provide comprehensive information about the oncogenic potential of TRIP13 in clinical significance for gliomas. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ssu-Han, Lin, Hong-Han, Li, Yao-Feng, Tsai, Wen-Chiuan, Hueng, Dueng-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150328/
https://www.ncbi.nlm.nih.gov/pubmed/34066132
http://dx.doi.org/10.3390/cancers13102338
_version_ 1783698125686308864
author Chen, Ssu-Han
Lin, Hong-Han
Li, Yao-Feng
Tsai, Wen-Chiuan
Hueng, Dueng-Yuan
author_facet Chen, Ssu-Han
Lin, Hong-Han
Li, Yao-Feng
Tsai, Wen-Chiuan
Hueng, Dueng-Yuan
author_sort Chen, Ssu-Han
collection PubMed
description SIMPLE SUMMARY: High expression of TRIP13 is associated with IDH-wild type gliomas. Patients with elevated TRIP13 levels are indicative of the poor survival outcome. The study aimed to provide comprehensive information about the oncogenic potential of TRIP13 in clinical significance for gliomas. We found that TRIP13 co-expressed genes implicated in tumorigenesis and therapeutic resistance may regulated by TP53 and FOXM1. The aberrant expression of TRIP13 in gliomas was uncovered to be regulated by distinct underlying mechanisms, including the DNA methylation and dysfunction of miRNA targeting (such as miR-29 family). TRIP13-expressing tumors also showed high aneuploidy levels and reduced ratio of CD8(+)/Treg, which have unfavorable effects on patient outcome. These results demonstrate that TRIP13 is crucial for tumor development and reveal the emerging therapeutic potential of gliomas. ABSTRACT: The prognosis of malignant gliomas such as glioblastoma multiforme (GBM) has remained poor due to limited therapeutic strategies. Thus, it is pivotal to determine prognostic factors for gliomas. Thyroid Receptor Interacting Protein 13 (TRIP13) was found to be overexpressed in several solid tumors, but its role and clinical significance in gliomas is still unclear. Here, we conducted a comprehensive expression analysis of TRIP13 to determine the prognostic values. Gene expression profiles of the Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA) and GSE16011 dataset showed increased TRIP13 expression in advanced stage and worse prognosis in IDH-wild type lower-grade glioma. We performed RT-PCR and Western blot to validate TRIP13 mRNA expression and protein levels in GBM cell lines. TRIP13 co-expressed genes via database screening were regulated by essential cancer-related upstream regulators (such as TP53 and FOXM1). Then, TCGA analysis revealed that more TRIP13 promoter hypomethylation was observed in GBM than in low-grade glioma. We also inferred that the upregulated TRIP13 levels in gliomas could be regulated by dysfunction of miR-29 in gliomas patient cohorts. Moreover, TRIP13-expressing tumors not only had higher aneuploidy but also tended to reduce the ratio of CD8(+)/Treg, which led to a worse survival outcome. Overall, these findings demonstrate that TRIP13 has with multiple functions in gliomas, and they may be crucial for therapeutic potential.
format Online
Article
Text
id pubmed-8150328
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81503282021-05-27 Clinical Significance and Systematic Expression Analysis of the Thyroid Receptor Interacting Protein 13 (TRIP13) as Human Gliomas Biomarker Chen, Ssu-Han Lin, Hong-Han Li, Yao-Feng Tsai, Wen-Chiuan Hueng, Dueng-Yuan Cancers (Basel) Article SIMPLE SUMMARY: High expression of TRIP13 is associated with IDH-wild type gliomas. Patients with elevated TRIP13 levels are indicative of the poor survival outcome. The study aimed to provide comprehensive information about the oncogenic potential of TRIP13 in clinical significance for gliomas. We found that TRIP13 co-expressed genes implicated in tumorigenesis and therapeutic resistance may regulated by TP53 and FOXM1. The aberrant expression of TRIP13 in gliomas was uncovered to be regulated by distinct underlying mechanisms, including the DNA methylation and dysfunction of miRNA targeting (such as miR-29 family). TRIP13-expressing tumors also showed high aneuploidy levels and reduced ratio of CD8(+)/Treg, which have unfavorable effects on patient outcome. These results demonstrate that TRIP13 is crucial for tumor development and reveal the emerging therapeutic potential of gliomas. ABSTRACT: The prognosis of malignant gliomas such as glioblastoma multiforme (GBM) has remained poor due to limited therapeutic strategies. Thus, it is pivotal to determine prognostic factors for gliomas. Thyroid Receptor Interacting Protein 13 (TRIP13) was found to be overexpressed in several solid tumors, but its role and clinical significance in gliomas is still unclear. Here, we conducted a comprehensive expression analysis of TRIP13 to determine the prognostic values. Gene expression profiles of the Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA) and GSE16011 dataset showed increased TRIP13 expression in advanced stage and worse prognosis in IDH-wild type lower-grade glioma. We performed RT-PCR and Western blot to validate TRIP13 mRNA expression and protein levels in GBM cell lines. TRIP13 co-expressed genes via database screening were regulated by essential cancer-related upstream regulators (such as TP53 and FOXM1). Then, TCGA analysis revealed that more TRIP13 promoter hypomethylation was observed in GBM than in low-grade glioma. We also inferred that the upregulated TRIP13 levels in gliomas could be regulated by dysfunction of miR-29 in gliomas patient cohorts. Moreover, TRIP13-expressing tumors not only had higher aneuploidy but also tended to reduce the ratio of CD8(+)/Treg, which led to a worse survival outcome. Overall, these findings demonstrate that TRIP13 has with multiple functions in gliomas, and they may be crucial for therapeutic potential. MDPI 2021-05-12 /pmc/articles/PMC8150328/ /pubmed/34066132 http://dx.doi.org/10.3390/cancers13102338 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Ssu-Han
Lin, Hong-Han
Li, Yao-Feng
Tsai, Wen-Chiuan
Hueng, Dueng-Yuan
Clinical Significance and Systematic Expression Analysis of the Thyroid Receptor Interacting Protein 13 (TRIP13) as Human Gliomas Biomarker
title Clinical Significance and Systematic Expression Analysis of the Thyroid Receptor Interacting Protein 13 (TRIP13) as Human Gliomas Biomarker
title_full Clinical Significance and Systematic Expression Analysis of the Thyroid Receptor Interacting Protein 13 (TRIP13) as Human Gliomas Biomarker
title_fullStr Clinical Significance and Systematic Expression Analysis of the Thyroid Receptor Interacting Protein 13 (TRIP13) as Human Gliomas Biomarker
title_full_unstemmed Clinical Significance and Systematic Expression Analysis of the Thyroid Receptor Interacting Protein 13 (TRIP13) as Human Gliomas Biomarker
title_short Clinical Significance and Systematic Expression Analysis of the Thyroid Receptor Interacting Protein 13 (TRIP13) as Human Gliomas Biomarker
title_sort clinical significance and systematic expression analysis of the thyroid receptor interacting protein 13 (trip13) as human gliomas biomarker
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150328/
https://www.ncbi.nlm.nih.gov/pubmed/34066132
http://dx.doi.org/10.3390/cancers13102338
work_keys_str_mv AT chenssuhan clinicalsignificanceandsystematicexpressionanalysisofthethyroidreceptorinteractingprotein13trip13ashumangliomasbiomarker
AT linhonghan clinicalsignificanceandsystematicexpressionanalysisofthethyroidreceptorinteractingprotein13trip13ashumangliomasbiomarker
AT liyaofeng clinicalsignificanceandsystematicexpressionanalysisofthethyroidreceptorinteractingprotein13trip13ashumangliomasbiomarker
AT tsaiwenchiuan clinicalsignificanceandsystematicexpressionanalysisofthethyroidreceptorinteractingprotein13trip13ashumangliomasbiomarker
AT huengduengyuan clinicalsignificanceandsystematicexpressionanalysisofthethyroidreceptorinteractingprotein13trip13ashumangliomasbiomarker